Question 1

What is the catalog number for MreB Inhibitor A22, Disrupts bacterial actin cytoskeleton?

Accepted Answer

The catalog number for MreB Inhibitor A22, Disrupts bacterial actin cytoskeleton is TBI5275-10MG.

Question 2

What sizes are available for MreB Inhibitor A22, Disrupts bacterial actin cytoskeleton?

Accepted Answer

MreB Inhibitor A22, Disrupts bacterial actin cytoskeleton is available in the following size(s): 10 mg.

Question 3

Is MreB Inhibitor A22, Disrupts bacterial actin cytoskeleton in stock?

Accepted Answer

MreB Inhibitor A22, Disrupts bacterial actin cytoskeleton is currently made to order / not held in immediate stock. Contact us for lead time.

Question 4

Do you offer custom or private-label production of this type of product?

Accepted Answer

Yes, custom antibody development and private-label production services are available. Contact our sales team to discuss your target, timeline, and quantity requirements.

Question 5

What is the immunogen used to generate this antibody?

Accepted Answer

Immunogen or antigen details used to raise this antibody are listed on the product datasheet under immunogen information.

Question 6

What is the recommended positive control for this assay?

Accepted Answer

A recommended positive control, where one is specified by the manufacturer, is listed on the datasheet or in the assay protocol.

MreB Inhibitor A22, Disrupts bacterial actin cytoskeleton

Product Specifications

Shipping Conditions

Frequently Asked Questions

Explore Other Products

Aurora B (Proliferation Marker) (AURKB/1845), CF740 conjugate, 0.1mg/mL

MMP9 (Matrix Metalloproteinase 9) (2C3), CF640R conjugate, 0.1mg/mL

CD63 (MX-49.129.5), CF405S conjugate, 0.1mg/mL

CD63 (LAMP3/968), CF740 conjugate, 0.1mg/mL

P63 (Squamous, Basal & Myoepithelial Cell Marker) (TP63/2428), CF488A conjugate, 0.1mg/mL

PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF594 conjugate, 0.1mg/mL